Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06889974 | NOT YET RECRUITING | Renal Replacement Therapy for Acute Kidney Injury in ICU

Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
Sponsor:

University Hospital, Bordeaux

Brief Summary:

The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS) and associated acute kidney injury (AKI). The study will compare early versus delayed RRT initiation, examining the effect on renal function at 30 days post-treatment.

Condition or disease

Renal Replacement Therapy for Acute Kidney Injury in ICU

Detailed Description:

Tumor lysis syndrome (TLS) is a common and life-threatening complication in patients with hematologic malignancies, characterized by severe metabolic imbalances due to rapid tumor cell destruction. This syndrome frequently leads to acute kidney injury (AKI), requiring renal replacement therapy (RRT) in about 50% of cases. Despite its clinical significance, there is a lack of consensus on the optimal timing of RRT initiation in TLS-related AKI. Studies in other forms of AKI suggest no difference in outcomes between early and delayed RRT initiation, but these results are not directly applicable to TLS patients. This study seeks to fill this gap by analyzing the timing and outcomes of RRT initiation in TLS patients. The retrospective study will collect data from multiple intensive care units (ICUs) across France. Procedure: The study will retrospectively analyze patient data from 2013 to 2023, comparing early vs. delayed RRT initiation. Follow-up: Data on renal function, RRT usage, and mortality will be collected 30 days and one year after ICU admission.

Study Type : OBSERVATIONAL
Estimated Enrollment : 800 participants
Official Title : Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
Actual Study Start Date : 2025-05
Estimated Primary Completion Date : 2026-05
Estimated Study Completion Date : 2026-05

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Adults aged ≥18 years.
  • * Hospitalized in the ICU between January 1, 2013, and December 31, 2023.
  • * Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy.
  • * Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation.
Exclusion Criteria
  • * Patient or family opposition to data collection for research purposes.
  • * Incomplete medical records that preclude data extraction.
Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome

Location Details

NCT06889974

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

France,

CHU d'Angers

Angers, France,

Not yet recruiting

France,

Pellegrin Hospital

Bordeaux, France,

Not yet recruiting

France,

La Cavale Blanche Hospital

Brest, France,

Not yet recruiting

France,

chu dupuytren

Limoges, France,

Not yet recruiting

France,

Hôtel-Dieu

Nantes, France,

Not yet recruiting

France,

CHR d'Orléans

Orléans, France,

Not yet recruiting

France,

Pau ch

Pau, France,

Not yet recruiting

France,

Emergency-resuscitation center

Rennes, France,

Not yet recruiting

France,

Bretonneau Hospital

Tours, France,